CK␤-11 chemoattracts T cells, B cells, dendritic cells, macrophage progenitors, and NK cells and facilitates dendritic cell and T cell interactions in
B
reast cancer is the most common cancer in American women and the second most common cause of cancer death (1) . Adjuvant chemotherapy and radiation have improved the survival of women presenting with localized disease, but subsets of women continue to have a poor prognosis (2) (3) (4) . Metastatic breast cancer has a uniform poor outcome with a median survival rate of ϳ2 years (3) .
Various cytokines and chemokines are known to have antitumor activity, and cytokine-expressing autologous tumor cell vaccines can enhance antitumor immune responses against malignant cells in vivo. Rejection of tumor cells has been noted in various murine tumor models in which tumor cells have been modified with early acting cytokines (GM-CSF, Flt3L, G-CSF) (5) (6) (7) (8) , immunoregulatory cytokines (IL-2, IL-4, IL-7, IL-10, IL-12) (9 -13), inhibitory cytokines (TNF-␣, IFN-␥) (14, 15) , chemokines (MIP-1␣, 3 RAN-TES, lymphotactin, TCA3, JE/MCP-1/MCAF) (16 -23) , and costimulatory molecules (CD40L, B7.1) (24, 25) .
Chemokines are a large family of cytokines with four subgroups (CC, CXC, CX 3 C, and C) based on the N-terminal cysteine motifs (26, 27) . The CC chemokine CK␤-11/MIP-3␤/ELC/Exodus 3 (CK␤-11) chemoattracts T cells (28 -31) , B cells (29, 30) , dendritic cells (DC) (32) , macrophage progenitor cells (33) , and NK cells (29) , and may be involved in the interactions of DC and T cells in secondary lymphoid tissues (28, 34) .
Since CK␤-11, expressed in the secondary lymphoid tissues, has the potential to induce specific homing of most lymphoid cells and of DC, we hypothesized that in vivo expression of CK␤-11 in the murine breast cancer cell line C3L5 may generate antitumor immunity by facilitating localization of lymphocytes and DC at the site of tumorigenesis. After vaccinating animals with CK␤11-transduced C3L5 cells, we found rejection of the CK␤-11-transduced tumor was mediated through NK cells and CD4 ϩ cells (including CD4
ϩ NKT cells), while antitumor immunity in a subsequent challenge with parental C3L5 cells required CD4 ϩ cells at the time of C3L5-CK␤11 vaccination. These results suggest, for the first time, two levels of antitumor activity for CK␤-11; one level is mediated mostly through NK cells, and another is mediated through CD4 ϩ cells.
Materials and Methods

Construction of the retroviral vector
The cDNA for CK␤-11 was generated by RT-PCR of total mRNA from human PBMC. After reverse transcription with oligo(dT) primer and Superscript II (Life Technologies, Rockville, MD), the forward primer (5Ј-GTT CGG TAC CTG CCT CTG TTC ACC CTC CAT G-3Ј) and the  reverse primer (5Ј-AGT GCT CGA GTT ACT TGT CAT CAT CGT CCT  TGT AGT CAC TGC TGC GGC GCT TCA TCT T-3Ј) were used to amplify the complete coding sequence. PCR product was digested with XhoI and KpnI and cloned into the expression vector pREP4 (Invitrogen, Carlsbad, CA). Cloning of CK␤-11 cDNA was confirmed by sequencing (35) . pREP4-CK␤-11 was transfected into 293-EBNA cells (Invitrogen) by a standard electoporation method, and hygromycin-resistant cells were selected at 400 g/ml of hygromycin. Supernatants from 293-EBNA cells and 293-EBNA-CK␤-11 cells were tested for chemotactic activity for NKL cells, as previously described (29) . Three-day culture supernatants from 293-EBNA-CK␤-11, but not 293-EBNA cells, showed a chemotactic activity equal to that of 50 -100 ng/ml control CK␤-11 protein (30) .
The retroviral vector L(CK␤11)SN (see Fig. 1B ) was generated by cloning the 350-bp cDNA fragment from EBNA-CK␤-11 into the EcoRI and XhoI sites of pLXSN (36) with CK␤-11 transcriptionally regulated by the Moloney murine leukemia virus (Mo-MLV) long terminal repeat (LTR). Correct orientation was verified by sequence analysis (Biochemistry Biotechnology Facility, Indiana University School of Medicine, Indianapolis, IN).
Cell culture
C3L5 (37, 38) , AM12 (39) , and GPϩE86 (40) cells were cultured in DMEM (BioWhittaker, Walkersville, MD) supplemented with 10% FBS (HyClone, Logan, UT), 100 U/ml penicillin, and 100 g/ml streptomycin (BioWhittaker) at 37°C with 5% CO 2 . The NK cell line NKL was cultured in RPMI 1640 (BioWhittaker) plus 15% FBS, 100 U/ml penicillin, 100 g/ml streptomycin, 1 mM sodium pyruvate, and 100 U/ml IL-2 (R&D Systems, Minneapolis, MN) at 37°C with 5% CO 2 .
Gene transfer
The retroviral vector L(CK␤11)SN was shuttle packaged through the ecotropic packaging cell line and GPϩE86 into the amphotropic packaging cell line AM12. Supernatant (0.45 m filtered) from these cells plus Polybrene (8 g/ml; Sigma, St. Louis, MO) was used to transduce the murine breast cancer cell line C3L5 (C3L5-CK␤11), as previously described (6, 7), before selection in media containing G418 (400 g/ml; Life Technologies/ BRL, Grand Island, NY). Fig. 1 represents a schematic of the retroviral vectors used in these studies. G1N (neo control)-transduced murine breast cancer cells (C3L5-G1N) were described in our previous study (6) . The vector G1Na (see Fig. 1A ) was provided by Genetic Therapy (Gaithersburg, MD).
Chemotaxis assay
Cultures of untransduced, C3L5-G1N and C3L5-CK␤-11 cells (1.5 ϫ 10 6 ) were plated in 3 ml DMEM without serum or with 10% FCS for 48 or 72 h. Cellular debris was removed from the conditioned media by filtering or centrifugation. NKL cells were washed in PBS and resuspended in DMEM plus 0.5% BSA chemotaxis media. Costar Transwells (6.5 mm diameter, 5 m pore size, polycarbonate membrane; Cambridge, MA) were used to separate the conditioned media from NKL cells for 3-4 h at 37°C with 5% CO 2 . The number of cells that transmigrated through the membrane were counted using the FACScan cell analyzer (Becton Dickinson, San Jose, CA), and chemotaxis was calculated as the percentage of the input cells.
In vivo studies
To determine the protection from tumor growth by CK␤-11, mice were vaccinated with 1 ϫ 10 4 transduced cells injected s.c. into the anterior chest wall of female C3H/HeN mice (tumor vaccine). Tumor growth was measured weekly and tumor volume was calculated (vol ϭ width 2 ϫ length/2). Animals tumor free at 4 wk were rechallenged with 1 ϫ 10 4 parental C3L5 cells in the contralateral chest wall (parental tumor challenge). Animal studies were reviewed and approved by the Institutional Review Board.
In adoptive transfer studies, 1 ϫ 10 7 splenocytes from animals tumor free after 4 wk were harvested and injected i.v. into previously untreated (naive) mice that simultaneously received 1 ϫ 10 4 untransduced C3L5 cells in the anterior chest wall.
To understand the mechanism and cellular mediators of antitumor activity, mice were injected with PBS, control rabbit serum (100 l i.p. per mouse on days Ϫ3, 0, and ϩ3) (Sigma), rabbit anti-asialo-GM1 to immunodeplete NK cells (20 l i.p. per mouse every 4 days during the primary tumor challenge or on days Ϫ3, 0, and ϩ3) (Wako Pure Chemical Industries, Richmond, VA), anti-CD4 (clone GK1.5; PharMingen, San Diego, CA), and anti-CD8 (clone 53-6.7; PharMingen) Abs (0.1 mg per mouse on days Ϫ3, 0, and ϩ3).
Statistical analysis
Differences in tumor growth were evaluated over 4 wk by the number of animals with tumor and by the tumor volume in these animals. Tumor growth was determined using the Mann-Whitney statistic for nonparametric analysis and the one-tailed critical values of U s , as described (41) . Differences in chemotactic responses and splenocyte percentages were evaluated by Student's t test.
Flow-cytometric analysis
Single-cell suspensions of splenocytes were resuspended in PBS with 0.5% BSA and dual stained by incubation with FITC-conjugated anti-CD3⑀ (clone 145-2c11; PharMingen) or the appropriate isotype control (PharMingen), and with PE-conjugated anti-CD4 (clone RM4-5; PharMingen), PE-conjugated anti-CD8 (clone 53-6.7; PharMingen), PE-conjugated antipan NK cells (clone DX5; PharMingen), or the appropriate isotype control (PharMingen) for 1 h at 4°C. C3L5 cells were stained with FITC-conjugated anti-CD1␦ (clone 1B1; PharMingen) and the appropriate isotype control (PharMingen). The cells were washed and analyzed for the percentage of cells in each population by flow cytometry using the FACScan cell analyzer (Becton Dickinson).
Results
Transduction and expression of the chemokine CK␤-11 in the murine breast cancer cell line C3L5
To assess the effectiveness of CK␤-11 as a tumor vaccine, we generated the full-length cDNA by RT-PCR and constructed the retroviral vector L(CK␤11)SN with CK␤-11 transcriptionally regulated by the Mo-MLV LTR and the neo gene transcriptionally regulated by the SV40 early promoter (Fig. 1B) . After shuttle packaging this retroviral vector was used to transduced the murine breast cancer cell line C3L5 before selection in medium containing G418 (C3L5-CK␤11). The control vector G1Na, containing the neo gene transcriptionally regulated by the Mo-MLV LTR (Fig.  1A) , was also used to generate a control cell line (C3L5-G1N), as previously described (6, 7) .
To measure the level of mRNA expression from the integrated provirus, Northern analysis was performed on total cellular RNA isolated from C3L5, C3L5-G1N, and C3L5-CK␤11 cell populations (Fig. 2) . Because the vectors contain the neomycin phosphotransferase gene as a common sequence, a neo-specific probe was used for hybridization. The parental C3L5 cells do not hybridize to the neo probe (Fig. 2, lane 1) . In contrast, the C3L5-G1N-and C3L5-CK␤11-transduced populations hybridized to the neo-specific probe with higher levels of neo expression in C3L5-G1N than in C3L5-CK␤11 (Fig. 2, lanes 2 and 3) . With the C3L5-CK␤11-transduced cells, two transcript lengths are evident (Fig. 2, lane 3) , consistent with expression from the LTR and the SV40 promoters. This molecular analysis demonstrates expression of the retroviral messenger RNA from the integrated provirus in transduced cells.
To demonstrate production of the chemokine CK␤-11, we measured the functional activity of CK␤-11 in conditioned media, as Abs against murine CK␤-11 are not commercially available. Supernatant from parental C3L5 and C3L5-CK␤11-transduced populations and a soluble rCK␤-11 positive control (100 ng/ml) were studied for chemoattractant potential in chemotaxis assay with the human NK cell line NKL. As shown in Table I , a previously determined optimal concentration of CK␤-11 (100 ng/ml) attracted 42 Ϯ 11% of input NKL cells through the membrane (mean for three separate experiments). From previous studies, the maximum sensitivity of this assay is ϳ1 ng/ml and the responsiveness of NKL cells to CK␤-11 is bell shaped, with concentrations higher than 100 ng/ml desensitizing chemotaxis (29) . Supernatant from the C3L5-CK␤11 cells attracted 24 Ϯ 3.4% of the NKL cells through the membrane, while only 5 Ϯ 2.2% of cells transversed the membrane when supernatant from the parental C3L5 cells was tested (Table I) . Although we cannot determine the precise concentration, from these results, we concluded that C3L5-CK␤11 supernatants contain between 1 and 10 ng/ml of CK␤-11 (0.5-10 ng/10 6 cells/24 h) and that these cells produce biologically relevant levels of CK␤-11 protein.
To determine the effect of CK␤-11 expression on the growth of C3L5 cells, the growth rate of transduced cells was studied. As shown in Fig. 3 , expression of the chemokines in C3L5 cells did not significantly ( p Ͼ 0.05) alter the in vitro growth rate of these cells compared with parental C3L5 and with G1N-transduced C3L5 cells.
Tumor vaccine and parental tumor challenge
To determine whether chemokine expression prevented tumor formation, female C3H/HeN mice were vaccinated with 1 ϫ 10 4 C3L5-G1N or C3L5-CK␤11 cells s.c. in the anterior chest wall (tumor vaccine). Animals were followed for 4 wk, and tumor volume and the percentage of tumor-free animals (TFA) were determined. After inoculation with the tumor vaccine (Fig. 4) , C3L5-CK␤11-vaccinated mice (90% TFA, vol ϭ 1.9 cm 3 ) had FIGURE 2. Molecular analysis of retroviral mRNA expression. Total RNA from C3L5, C3L5-G1N, and C3L5-CK␤11 cells was isolated, separated by gel electrophoreses, and blotted to nylon membranes. Membranes were probed with a radiolabeled neomycin phosphotransferase (Neo)-specific probe. After washing, the membrane was exposed to film for 6 h. Bottom frame, Ethidium bromide (EtBr) staining of RNA gel shows equal loading of samples. Top frame, Neo-specific hybridization to C3L5-G1N and C3L5-CK␤11. The arrows show multiple transcript lengths in C3L5-CK␤11 cells resulting from the two promoters. significantly decreased tumor formation ( p Ͻ 0.05) when compared with control C3L5-G1N-vaccinated animals (0% TFA, vol ϭ 1.6 Ϯ 0.29 cm 3 ). To determine whether C3L5-CK␤11-vaccinated animals had generated tumor immunity, TFA at 4 wk were rechallenged with 1 ϫ 10 4 parental C3L5 cells in the contralateral chest wall (parental tumor challenge). During this secondary challenge with parental C3L5 cells (Fig. 4) , vaccination with C3L5-CK␤11 significantly reduced ( p Ͻ 0.05) the tumor growth, but did not prevent tumor formation (11% TFA, vol ϭ 0.87 Ϯ 0.45 cm 3 ). These results indicate that CK␤-11-transduced cells can mediate tumor rejection and generate a low level of antitumor immunity.
Immunodepletion of lymphoid subsets with Ab injections
Several mechanisms may be involved in generating antitumor activity by CK␤-11-transduced C3L5 cells. Because CK␤-11 is known to chemoattract effector cells, such as naive and memory T cells and NK cells, we studied the role of CD4 ϩ , CD8 ϩ , and NK cells in CK␤-11 antitumor activity by immunodepleting these cells in vivo with Abs. As shown in Fig. 5 , immunodepletion of NK cells with anti-asialo-GM1 and of CD4 ϩ cells with anti-CD4 during the C3L5-CK␤11 vaccination period, resulted in reduction of CK␤-11 antitumor activity ( p Ͻ 0.05) (0% TFA, vol ϭ 1. 
CD4
ϩ NK cells, during immunodepletion with anti-CD4, the percentage of DX5 ϩ CD3 ϩ splenocytes (2.5%) was also significantly reduced (58%; p Ͻ 0.05) compared with normal controls (6 Ϯ 1.3%). These results indicate that the target subpopulations were substantially reduced by the Ab treatments.
Transfer of splenocytes from vaccinated and immunodepleted animals
To determine the role of the various subpopulations in the generation of acquired immunity, splenocytes from animals immunodepleted of lymphocyte subsets during C3L5-CK␤11 vaccination were transferred to naive animals during challenge with parental C3L5 cells. Transfer of splenocytes from C3L5-CK␤11-vaccinated animals significantly reduced ( p Ͻ 0.05) the tumor volume of the parental tumor challenge compared with PBS-treated or naive splenocyte-treated animals (Table III) . Treatment with antiasialo-GM1 and anti-CD8 did not inhibit the acquired immunity 
a Results presented are the percent of the total splenocytes that represent these phenotypes and the change in these populations as the result of the treatments. b Not significantly different ( p Ͼ 0.05) from normal untreated or rabbit serum-treated animals. generated during the C3L5-CK␤11 vaccination, as the adoptive transfer of splenocytes from these animals significantly reduced ( p Ͻ 0.05) tumor volume compared with control animals (Table  III) . In contrast, adoptive transfer of splenocytes from the anti-CD4-depleted animals lost this acquired immunity, as tumor volume was not significantly different ( p Ͼ 0.05) than controls (Table  III) . Although adoptive immunity was apparent with the transfer of splenocytes, no in vitro antitumor activity was detectable (data not shown). These results indicate that C3L5-CK␤11 vaccination generates some level of transferable immunity and that this response is not generated through NK ϩ or CD8 ϩ cells, but through CD4 ϩ cells.
Discussion
Chemokines were originally identified and described by their involvement in the inflammatory response and their capacity to chemoattract leukocytes. However, it has recently been observed that some chemokines influence the trafficking of lymphocytes to primary (thymus), secondary (lymph nodes), and tertiary (periphery) lymphoid tissues (34) . CK␤-11, a ligand for CCR7 (35) , is expressed at high level in the thymus and in the lymph nodes, constitutively in DC within the T cell zone of the lymph node, and is also known to strongly chemoattract CD8 ϩ T cells, naive CD4 ϩ T cells, mature DC, and NK cells. CCR7 was found recently to coordinate the primary immune response in receptor knockout mice, as naive T cells and activated skin DC are unable to migrate into the lymph nodes (43) . We hypothesized that expression of CK␤-11 in tumor cells would facilitate the formation of antitumor immunity, an effect possibly mediated by NK cells and lymphocytes.
These results indicate, for the first time, that expression of CK␤-11 in a tumor model inhibited formation of the transduced tumor (even though in vitro growth of the transduced tumor cell was not effected) and that CK␤-11-transduced tumor vaccine generated antitumor immunity in vivo. These results also suggest that NK cells and CD4 ϩ cells are involved in the antitumor activity elicited by CK␤-11 and that CD4 ϩ cells are necessary for establishing antitumor immunity.
Many immunoregulatory molecules have been shown to mediate antitumor activity in a variety of tumor models. The murine breast cancer cell line C3L5 used in these studies is poorly or nonimmunogenic, as 10 6 irradiated C3L5 cells offer no protection against future tumor challenges (data not shown). We have previously shown that both Flt3L-and GM-CSF-transduced C3L5 cells generate antitumor immunity (6, 7) . Flt3L and GM-CSF are both known to stimulate proliferation and differentiation of DC (44 -46) , although the immunity generated with Flt3L-transduced tumor vaccine was stronger than GM-CSF-and CK␤-11-transduced tumor vaccines ( (7) and these data). Flt3L is also known to stimulate proliferation of NK cells in vivo (47, 48) , and we showed that NK cells are involved in mediating antitumor activity of Flt3L-transduced tumor cells (7). CK␤-11 does not activate NK cells (data not shown), but does chemoattract both DC and NK cells (29, 32) .
Several groups have shown antitumor activity with a variety of chemokines. With nine known CC chemokine receptors and five known CXC chemokine receptors, expression of receptors in the lymphoid cells varies widely. Additionally, the specificity of chemokine receptors is promiscuous, allowing for redundant activity of several chemokines on leukocytes that express the receptor. Therefore, the type of infiltrating leukocytes is determined by the expression profile of chemokines (34) .
Studies have shown antitumor activity for MIP-1␣, RANTES, lymphotactin, and TCA3 (16 -19) . MIP-1␣ expression in adenocarcinoma cells, but not IL-8 expression, led to reduced tumor formation and increased infiltration of macrophages and neutrophils (18) . After subsequent challenges with MIP-1␣-expressing and parental tumor cells, protective immunity was also observed (18) . With TCA3 expression, tumor formation was inhibited and tumor-specific immunity was generated; however, histological analysis revealed mostly neutrophils around the TCA3-expressing tumor (17) . RANTES also inhibited tumor formation and generated tumor immunity (16) . Additionally, immunodepleting CD8 ϩ T cells, blocking macrophage migration with Abs to adhesion receptors, and, to a lesser extent, immunodepleting CD4 ϩ T cells all restored RANTES-transduced tumor formation (16) . Lymphotactin, by itself, reduced tumor growth; however, in combination with IL-2, it enhanced antitumor immunity and inhibited an established tumor (19) . These interactions were mediated through CD4 ϩ and CD8 ϩ T cells (19) . JE/MCP-1/MCAF (MCP-1) was shown to reduce in vivo growth of tumor cells and increase infiltration of macrophages/ monocytes to the tumor site (20 -23) . Localization of fibroblasts engineered to express MCP-1 recruits migration of macrophages to the lungs and suppresses lung metastasis of renal adenocarcinoma (21) . This may occur because MCP-1 and LPS are synergistic in activating cytotoxicity of macrophages against tumor cells (49) . Additionally, the combined expression of MCP-1 and the addition of Abs against P-glycoprotein inhibited tumor formation of multidrug-resistant lung cancer cells in vivo (22) .
In the normal host immune response, DC acquire Ag and present them to CD4 ϩ and CD8 ϩ T cells through MHC class I and II molecules. NK cells will kill a target cell unless a signal from the target cell MHC class I is received through the NK cell inhibitory receptor Ly-49A (50). Expression of cytokines or chemokines in the tumor cells stimulates the normal immune response to mediate the antitumor response. Host immune cells may infiltrate the tumor site, proliferate, differentiate, secrete other secondary cytokines or chemokines, recruit other effector cells, or become activated, eventually targeting tumor cells for destruction.
Because DC are chemoattracted by CK␤-11, these cells may be involved in presenting tumor-specific Ag to the CD4 ϩ cells that are mediating the antitumor immunity. Studies have demonstrated that Ag-activated CD4 ϩ NKT cells express CD40 ligand (CD154) and engage the CD40 receptor on APC, which then produce IL-12 (51) for the activation of NKT cells (52) . The transduced tumor cells are probably not presenting the tumor-specific Ag to the NKT cells, as we found that C3L5-CK␤11 cells had equivalent levels of CD1␦ expression as C3L5-G1N cells (data not shown). As noted previously, IFN-␥ expression in C3L5, although it raises the level of MHC class I and II expression, does not mediate antitumor responses as strong as that of Flt3L expression (7). Although Flt3L is known to stimulate DC and NK cells, we found a predominate role for NK cells in antitumor activity in this tumor model. It has been suggested that effector cells in innate immunity play a pivotal role in shaping initial T cell activation (51), possibly by conditioning DCs for subsequent immune responses (52) . NKT cells are CD3 ϩ T cells that also express NK cell markers and usually the invariant V␣14-J␣281 chain of the TCR (53) to interact with CD1␦ (MHC-like) molecules on APC (54) . NKT cells are important in IL-12-mediated antitumor activities, as mice with a deletion of CD1 gene or the J␣281 gene segment, and the subsequent loss of NKT cells could no longer mediate the IL-12-induced rejection of tumors (13) . These studies have not separated the effects of the NK ϩ CD3 Ϫ cells or NK ϩ CD3 ϩ NKT cells from the CD4 ϩ CD3 ϩ T cells in generating antitumor activity or priming immunity against the transduced tumor cells.
Our results with CK␤-11 suggest two levels of responsiveness: antitumor activity against the transduced cells mediated mostly by NK ϩ cells, and antitumor immunity mediated through CD4 ϩ cells. More recently, several groups showed that MCP-1, MIP-1␣, and RANTES chemoattract immature DC migration (32, 55) , and that MCP-1 also activate CTL and NK cytolytic responses (56) . Our results with CK␤-11 and Flt3L support the notion that NK cells activate adaptive immunity and may suggest a common mechanism for antitumor activity with other stimulatory molecules. Whether these same interactions are responsible for the increased antitumor response we observed with Flt3L compared with GM-CSF or CK␤-11 needs further studies.
Because chemokines have important functions in host defenses, they may be used to modulate other activities, such as antitumor immunotherapy. Local expression of chemokines by transduced tumor cells may augment other therapeutic modalities, particularly those that stimulate DC, NK cells, or T cells, such as GM-CSF, Flt3L, IL-2, IFN-␥, or IL-12. Future studies are necessary to support its role in clinical immunotherapeutic trials.
